Research aims to optimize brain’s defense mechanisms to combat TBI
By Jan Jarvis
An estimated 1.7 million people in the United States experience loss of cognitive and sensorimotor functions following TBI annually. Those who survive the initial injury often cope with enormous losses in productivity, independence and quality of life.
Researchers at UNT Health Science Center, in collaboration with Epigen Biosciences Inc., a pharmaceutical company in San Diego, are exploring a family of novel compounds that could change how these injuries are treated. This Phase I study is funded by a $417,000 grant from the National Institutes of Health.
The path to clinically effective solutions for TBI is riddled with bumps and puddles, said Victor Uteshev, PhD, Associate Professor of Pharmacology & Neuroscience. TBI presents a considerable intellectual challenge because it is such a complex personal disorder. The concept of individualized medicine is highly relevant to TBI.
“Rephrasing Leo Tolstoy: Healthy brains are all alike, but every traumatically injured brain is unhealthy in its own way,” Dr. Uteshev said. “As a result, development of standardized treatments suitable for all or even many traumatically injured brains is a tremendous challenge. But solving scientific challenges is our job, not inconvenience.”
Despite multiple failures of other approaches in the treatment of TBI, Dr. Uteshev remains optimistic about his novel approach “because we have a powerful ally – nature. The human brain has an intrinsic ability to defend itself from injuries. The defense mechanisms that we study employ the Alpha-7 nicotinic receptors that are very common.”
A balanced activation of Alpha-7 receptors is beneficial for human health. Whenever a brain injury occurs, two simultaneous processes are automatically initiated as the injury stimulates Alpha-7 receptors. First, the brain tissue near the site of injury becomes protected from spreading injury. Then the injury-induced inflammation is mitigated to prevent additional injury.
What Dr. Uteshev proposes is to optimize these two processes by a single class of drugs called positive allosteric modulators of Alpha-7 receptors.
“These drugs may help achieves a healthy balance by modulating natural activation of Alpha-7 receptors after TBI,” he said. “We believe that our novel approach may eventually allow clinicians to optimize the hardwired natural defense mechanisms that are already pre-installed.”
By Jan Jarvis About halfway through a ballet season filled with graceful leaps and pounding landings, dancer Celesta Gaiera had not suffered a single injury. Physical therapy, massage and compression boots helped keep the Texas Ballet Theatre dancer on her feet through “Cinderella,” “Cl...Read more
Aug 19, 2019
By Jan Jarvis UNT Health Science Center and its community partners are expanding their efforts to improve health care for older adults with the support of a $3.75 million federal grant. The Health Resources and Services Administration funding will address the growing needs of older a...Read more
Aug 15, 2019
By Sally Crocker As Beatle Ringo Starr once wrote, “You know, it don’t come easy.” For Dr. Carolyn Bradley-Guidry (DrPH ’19), the turning point came midway through her UNT Health Science Center public health doctoral degree program. The first in her family to graduate from colle...Read more
Aug 13, 2019
By Steven Bartolotta Nationwide, interest in the study of pediatric nephrology, which focuses on kidney disease in children, is declining. In 2017, 40 percent of the available fellowships in the specialty went unfilled. That didn’t faze Dr. Kim Piburn, a 2016 Texas College of Osteo...Read more
Aug 12, 2019